Arbutus Biopharma
ABUS
ABUS
127 hedge funds and large institutions have $88.4M invested in Arbutus Biopharma in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 33 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
1.29% more ownership
Funds ownership: 29.8% → 31.09% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
26% less capital invested
Capital invested by funds: $119M → $88.4M (-$30.7M)
Holders
127
Holding in Top 10
2
Calls
$1.95M
Puts
$1.25M
Top Buyers
| 1 | +$5.07M | |
| 2 | +$2.42M | |
| 3 | +$925K | |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$691K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$529K |
Top Sellers
| 1 | -$5.19M | |
| 2 | -$1.53M | |
| 3 | -$533K | |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$209K |
| 5 |
Goldman Sachs
New York
|
-$189K |